Start Β· Catalogue Β· Profile Β· Table
Screening BODY HANDBOOK
Screening Β· Β§130
Fatty Liver Disease (MASLD)
About a third of adults have fat building up in their liver, and most don't know it. The condition β€” renamed MASLD in 2023 β€” quietly raises the odds of dying from a heart attack, roughly doubles the risk of type 2 diabetes, and in a small fraction of cases scars the liver enough to kill you. Detection is cheap: four numbers on a standard blood panel feed a calculator called FIB-4 that flags whose livers are actually in trouble. Caught early, it reverses.
Test Β· Yearly Evidence Strong Chapter Screening

This is one of the largest under-diagnosed metabolic problems an average primary-care doctor sees. Lab values that look "normal" are reassuring about a third of the time when they shouldn't be β€” a third of people with advanced liver scarring have liver enzymes inside the normal range. The fix at the detection stage is a calculation done on labs you've probably already had drawn. The harder part β€” if it comes back high β€” is the same weight-loss and diet work that cardiometabolic risk would already prescribe. Two newly approved drugs reverse the scarring when lifestyle alone doesn't get there fast enough.

MASLD is a body-wide problem that shows up first in the liver. When the body resists insulin β€” usually because of visceral fat, sugar load, and inactivity β€” fat cells leak free fatty acids into the bloodstream and the liver itself starts manufacturing fat from excess carbohydrate. Triglycerides pile up inside liver cells. That's the steatosis on ultrasound. The cells that get the most stressed leak lipid intermediates that inflame their neighbours; immune cells move in; the liver's scar-making cells (stellate cells) wake up and start laying down collagen. That progression β€” fat to inflammation (called MASH) to scarring (called fibrosis) β€” runs through stages F0 to F4, where F4 is full cirrhosis Rinella et al. 2023.

Two things make the disease worse than its liver consequences alone. A fatty liver secretes hormone-like proteins called hepatokines that worsen insulin resistance in muscle and fat, and pumps out an atherogenic lipid profile β€” small dense LDL, high triglycerides, low HDL. That's the mechanical bridge to heart disease. It also doubles back: a liver that's pumping out insulin-resistance signals makes you more likely to develop type 2 diabetes, and diabetes accelerates the liver scarring Mantovani et al. 2021.

How bad it actually gets β€” and how reliably

The thing to keep in mind: most people with fatty liver are fine, and a small minority are in real trouble. The numbers separating the two are good.

The bulk of those deaths are from the heart, not the liver. A meta-analysis pooling 36 studies and roughly six million people found a 45% higher risk of heart attacks and cardiovascular death in adults with MASLD, independent of cholesterol, blood pressure, and BMI Mantovani et al. 2021. Cardiac causes lead at every fibrosis stage short of cirrhosis. The liver-as-cardiometabolic-amplifier story isn't a metaphor; the hepatokines and lipid abnormalities are how it works.

The diabetes pipeline is similarly clean. Pooled across 33 studies and half a million adults, MASLD more than doubles the risk of developing type 2 diabetes (HR ~2.2), and the risk grows with imaging severity and liver-enzyme elevation Mantovani et al. 2022.

The two-step test

Both the American and European hepatology guidelines (2023 and 2024) agree on the same simple pathway, and it costs essentially nothing on top of routine labs Rinella et al. 2023 EASL-EASD-EASO 2024.

This pathway exists because liver biopsy β€” the gold standard β€” is invasive, expensive, and impractical at the scale of a 30%-prevalence disease. FIB-4 is what stratifies who needs the more careful (and costly) look.

What "treatment" actually means

For almost everyone whose FIB-4 lands in the low or indeterminate range, the treatment is weight loss. The dose matters and is well characterised: in a 52-week trial that re-biopsied participants at the end, losing 5–7% of body weight resolved the inflammation in most people, and losing 10% reversed actual scarring in 45% of them Vilar-Gomez et al. 2015. The diet pattern with the most evidence is Mediterranean β€” olive oil, fish, vegetables, legumes, minimal ultra-processed food β€” and it works at the same weight loss as a low-fat comparator while improving insulin sensitivity faster EASL-EASD-EASO 2024. Eating in an earlier, shorter daily window β€” time-restricted eating β€” is one of the cheaper ways to start unloading the liver on top of the diet work. Two or three cups of coffee a day is associated with about a third less advanced scarring in cohort data; the mechanism (chlorogenic acids, caffeine acting on stellate cells) is plausible if not yet trial-confirmed Kennedy et al. 2024. Alcohol β€” even a few drinks a week β€” accelerates the scarring in MASLD specifically; the cleaner the cut, the better.

For people whose FIB-4 confirms moderate-to-advanced scarring (F2–F3), there are now two FDA-approved drugs β€” plus, for some, high-dose vitamin E remains an older, clinician-supervised option.

What most people get wrong

  • "My liver enzymes are normal, I'm fine." A Scottish population study found that a third of MASLD patients with advanced scarring or cirrhosis had ALT inside the conventional "normal" range of 31–54 U/L Marjot et al. 2024. The reference range was set decades ago against a population that itself was full of undiagnosed fatty liver. A normal ALT in someone with diabetes or a BMI of 30 should never close the question β€” FIB-4 should.
  • "Fatty liver only matters if it turns into cirrhosis." Cardiovascular disease β€” not the liver β€” is the leading cause of death in fatty liver disease, at every scarring stage short of full cirrhosis Mantovani et al. 2021. The liver-as-cardiometabolic-amplifier is the bigger story for almost everyone who has the condition.
  • "Only obese people get it." Roughly 10–20% of cases are in adults with a normal BMI, more in East and South Asian populations. Visceral fat doesn't always show on the outside, and a couple of common genetic variants β€” most notably in a gene called PNPLA3 β€” push people into MASLD at lower body weights EASL-EASD-EASO 2024.
  • "It's the old NAFLD with a new name." Roughly true β€” but the new diagnostic criteria explicitly require at least one cardiometabolic risk factor (overweight, high glucose, high blood pressure, abnormal lipids), which makes the diagnosis lock to the actual mechanism rather than to "not drinking enough to count as alcoholic." A new category β€” MetALD β€” covers the people who have both MASLD and significant alcohol intake; their progression is faster than either alone Rinella et al. 2023.

What happens if you keep ignoring it

The default reader here is a 45-year-old with a waistline that's drifted out by ten centimetres over the decade, a fasting glucose just into the pre-diabetes range, and labs that the doctor says "look basically okay." Almost certainly: fat in the liver. Probably: no symptoms anyone will mention at the physical.

The first decade is quiet. The friend who keeps mentioning that he's "tired all the time, no matter how much he sleeps" β€” that's often metabolic fatigue, and a fatty liver is part of the picture. The midday slump that gets blamed on the meeting load is partly that too. People around you don't see anything; you don't either, mostly. The scale moves slowly upward.

The second decade is where the picture sharpens. Diabetes shows up β€” across half a million tracked adults, the people with this condition were twice as likely to be diagnosed with type 2 diabetes within ten years Mantovani et al. 2022. The cardiologist's visit lands earlier than it should. A small fraction β€” maybe one in twenty β€” quietly progress to the kind of liver scarring that, untreated, becomes cirrhosis: belly fluid, fragile veins in the throat, a doubled risk of liver cancer if diabetes is in the mix too. The version of this story that ends with a transplant referral is rare; the version that ends with a cardiovascular event around 60 instead of 75 is not Mantovani et al. 2021.

The single grim number worth knowing: people whose biopsy shows full cirrhosis have roughly four times the all-cause death rate of people whose biopsy shows no scarring at all, over the same follow-up Ng et al. 2023. The window for changing that β€” for almost everyone reading this β€” is now.

What changes if you catch it

Early-stage MASLD reverses. Not as a marketing line β€” as a biopsy finding.

Weeks one to twelve. Insulin sensitivity improves before the scale does much; that's the same metabolic shift that takes the worst edges off afternoon fatigue. Sleep gets less interrupted. Liver enzymes start to drop on labs by the second or third month β€” usually halfway to normal in the people who hold the weight loss EASL-EASD-EASO 2024.

Months three to twelve. Lose 7% of body weight and most of the inflammation in the liver resolves. Lose 10% and about half the people who had real scarring see that scarring regress on biopsy β€” the disease backs up Vilar-Gomez et al. 2015. Triglycerides come down, HDL function recovers, blood pressure eases. The cardiometabolic risk number β€” the one that was quietly tripling your odds of a heart attack β€” comes back toward baseline. The version of you that masked afternoons with caffeine becomes the version that actually has afternoons.

Year two onward. The hardest part isn't getting here; it's not drifting back. Sustained weight loss is where lifestyle alone has the biggest dropout. If lifestyle isn't holding the line and the FIB-4 said you were already in trouble, this is where the newer drugs come in β€” both resmetirom and weekly semaglutide showed real fibrosis improvement on biopsy in their phase 3 trials, on top of the lifestyle work Harrison et al. 2024 Sanyal et al. 2025.

Decade scale. The trajectory the previous section described β€” the diabetes diagnosis, the early cardiac event, the small but real chance of cirrhosis β€” bends. Not abolished; the metabolic background doesn't disappear because the liver feels better. But the curve flattens, and the curve was the point.

Adjacent topics the reader may not realise are tied to this one: getting a fasting glucose and HbA1c on the same panel, the Mediterranean diet pattern as a treatment vehicle, weight loss as a clinical intervention (and the GLP-1 medications that now sit alongside it), and alcohol's outsized cost in anyone with metabolic risk already on the table.

Related in the handbook
Worsens / aggravates
  • β€” The diet that builds fatty liver is heavy on ultra-processed food and fructose; cutting it back is the core of the fix.
Helps
  • β€” When diet alone won't shift fatty liver, GLP-1 drugs drive the weight loss that reverses it β€” and cut the heart risk that rides along.
  • β€” For the subset whose fatty liver has progressed to scarring, resmetirom is the first approved drug that can bend the trajectory.
  • β€” For some people with advanced fatty liver, high-dose vitamin E is an evidence-backed, clinician-supervised option.
  • β€” If you're carrying fatty liver, trading sugary drinks for diet versions lowers liver fat β€” better still, switch to water.
  • β€” Coffee is one of the few things shown to lower liver-scarring risk in fatty liver disease β€” a couple of cups a day quietly works in your favour here.
  • β€” Eating in an earlier, shorter window is one of the cheaper ways to start unloading a fatty liver.
  • β€” Berberine is a third-tier option for fatty liver: modest reductions in liver fat, nowhere near a substitute for weight loss or the main drugs.
Diagnosis
  • β€” Fatty liver usually shows up first as small, unexplained changes on a routine liver panel β€” learn to read those six numbers.
Related
  • β€” MASLD is the metabolic, non-alcohol version of fatty liver β€” but alcohol piles on the same damage.
  • β€” Fatty liver pushes ferritin up, which is why a high ferritin doesn't always mean iron overload β€” read it alongside TSAT.
  • β€” Women with PCOS carry higher fatty-liver risk through the shared insulin resistance.
  • β€” Fatty liver roughly doubles your odds of type 2 diabetes β€” they're two faces of the same metabolic problem.
  • β€” Fatty liver tracks the fat wrapped around your organs, and a DEXA scan quantifies exactly that, often before the liver shows up on any other test.
  • β€” Before blaming fat alone for a struggling liver, iron-overload hemochromatosis is the other common cause worth ruling out.
  • β€” A genuinely more permeable gut is one documented feature of fatty liver β€” the real version of 'leaky gut,' not the supplement-aisle one.
Β·
130